Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biopharmaceutical pioneer leveraging computational discovery to advance novel cancer immunotherapies. This news hub provides investors and researchers with timely updates on clinical trials, strategic partnerships, and therapeutic innovations emerging from Compugen's AI-driven platform.
Access authoritative updates on key developments including COM701 (anti-PVRIG), COM902 (anti-TIGIT), and collaborative programs with industry leaders. Our curated news collection simplifies tracking of pipeline progress, peer-reviewed research publications, and milestone achievements in immuno-oncology.
Content spans clinical trial results, regulatory milestones, and partner collaboration updates, offering a comprehensive view of Compugen's position in next-generation cancer treatment development. Bookmark this page for streamlined access to verified information about therapeutic candidates and computational discovery breakthroughs.
Compugen Ltd. (CGEN) announced the publication of preclinical data on COM902, a novel anti-TIGIT therapeutic antibody, in Cancer Immunology, Immunotherapy. Key findings show that COM902 enhances anti-tumor immune responses by blocking TIGIT, which is expressed in various solid tumors. It demonstrates no T cell depletion activity, potentially preserving immune function. The ongoing Phase 1 trial for COM902 is expected to report initial results in Q4 2021, with further studies combining it with other therapies planned for H2 2021.
Compugen Ltd. (Nasdaq: CGEN) announced the publication of a review article in Cancer Discovery discussing the DNAM-1 axis's role in cancer immunotherapy. Co-authored by Drew Pardoll, M.D., Ph.D., the article covers key molecules such as DNAM-1, TIGIT, and PVRIG, highlighting their therapeutic relevance. It also discusses the potential of combining DNAM-1 axis blockers with PD-1/L1 agents, aiming to expand treatment options for new patient populations. Compugen is conducting Phase 1 studies on its anti-PVRIG antibody, COM701, and TIGIT-targeting antibody, COM902, focusing on the clinical evaluation of these approaches.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 AM ET. The presentation will be available via live webcast on Compugen's website, with an option for replay afterward. Compugen focuses on developing therapeutics for cancer immunotherapy, featuring its lead candidate COM701, which is in a Phase 1 clinical study. The company also has another candidate, COM902, targeting TIGIT, currently in a Phase 1 trial. Compugen operates from Israel and has a presence in South San Francisco, CA.
Compugen Ltd. (NASDAQ: CGEN) reported its financial results for Q4 and full year 2020. Revenues for Q4 were $2.0 million, primarily from a milestone payment from AstraZeneca. R&D expenses rose to $8.1 million in Q4 and $22.8 million for the year, driven by clinical studies and manufacturing activities. The net loss for Q4 was $8.6 million, with total cash reserves at approximately $124.4 million as of year-end. Compugen is focusing on expanding clinical programs for its immunotherapy candidates, showcasing encouraging data for COM701 in refractory cancer patients.
Compugen Ltd. (CGEN) announced updated data from its Phase 1 study of COM701, an investigational antibody targeting PVRIG, reporting a 66.7% disease control rate when combined with Opdivo®. Key results included a confirmed complete response in a previously unresponsive patient and ongoing durable responses over a year in several patients. The company plans to expand the study to include patients with ovarian, breast, endometrial, and colorectal cancers. Compugen aims to evaluate dual and triple blockade regimens, enhancing the potential of its innovative immunotherapy approach.
Compugen Ltd. (CGEN) announced an expanded clinical collaboration with Bristol Myers Squibb to evaluate COM701, a first-in-class anti-PVRIG antibody, in a Phase 1b cohort study. This study will combine COM701 with Opdivo® (nivolumab) and is set to begin in Q2 2021. Initial results from dose escalation show preliminary antitumor activity. The study will focus on patients with ovarian, breast, endometrial, and colorectal cancers, aiming to provide insights on treatment efficacy through monotherapy, dual, and triple combination therapies.
Compugen Ltd. (Nasdaq: CGEN) will release its fourth quarter and full year 2020 financial results on February 25, 2021, before U.S. markets open. A conference call will follow at 8:30 AM ET for management to discuss the results and provide updates. Compugen specializes in cancer immunotherapy and predictive target discovery, with key products COM701 and COM902 currently in Phase 1 clinical studies. The company is headquartered in Israel and has offices in South San Francisco, CA, with shares traded on Nasdaq and the Tel Aviv Stock Exchange.
Compugen Ltd. (Nasdaq: CGEN) announces participation in several virtual investor conferences. Key events include the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:40 AM ET, the Jefferies Virtual Healthcare Conference on November 18, 2020, at 5:35 AM ET, and the Evercore ISI HealthCONx Conference on December 1, 2020, at 9:40 AM ET. Live webcasts will be available on the Compugen website, with replays accessible post-event. The company is focused on cancer immunotherapy, with its lead product COM701 in Phase 1 clinical studies.
Compugen Ltd. (NASDAQ: CGEN) reported its Q3 2020 financial results, revealing a net loss of $7.8 million, or $0.09 per share, an increase from $6.5 million, or $0.10 per share, in Q3 2019. R&D expenses rose to $5.5 million from $4.3 million due to ongoing clinical studies. A noteworthy milestone was the initiation of a Phase 1/2 study for the anti-PVRIG antibody, COM701, in combination with Bristol Myers Squibb's Opdivo® and an investigational TIGIT antibody. Compugen's cash reserves reached approximately $133 million, significantly up from $44 million at year-end 2019.
Compugen Ltd. (CGEN) has received a new patent from the China National Intellectual Property Administration for COM902, an immuno-oncology therapeutic antibody targeting TIGIT. This patent extends the protection for COM902 beyond existing patents in the U.S. and Europe and covers its composition for cancer treatment. The patent is valid until at least August 2037. COM902 is currently in a Phase 1 clinical trial, showing potential to enhance T cell responses against tumors when combined with PD-1 inhibitors. This development reflects Compugen's commitment to expanding its immuno-oncology pipeline.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
